Antisoma Adopts Therex From Imperial Cancer Research Fund

has adopted a new clinical programme around Therex, a product based on the humanised monoclonal antibody huHMFG1 aiming to treat breast cancer.

Originally developed by the (ICRF), Therex is in a Phase I clinical study.

The antibody targets most common epithelial cancers, including breast, lung, ovarian, gastric and colorectal cancers.

Pre-clinical studies at Imperial Cancer Research Technology’s Applied Development Laboratory (ADL) have used a mouse breast cancer model to demonstrate improved survival for Therex-treated mice compared to untreated mice.

The ICRF Breast Cancer Biology Group, Guy’s Hospital is carrying out a Phase I clinical study to test the safety and tolerability of Therex following repeat administration.

Results from the eighteen patients with primary breast cancer treated so far indicate that the drug is well tolerated.

Antisoma will now progress Therex development into a Phase IIa clinical study and will contract with a third-party to provide clinical- grade material for the study, expected to start in the first half of 2001.

Antisoma’s Phase IIa study is likely to recruit those women who have relapsed following first-line treatment, of which there are approximately 112,000 cases each year.

Glyn Edwards, Antisoma’s CEO, said: “Recent advances in antibody therapy have given hope to about 30% of women who relapse following primary treatment for breast cancer. Therex could bring similar benefits to more women with this disease if it successfully completes clinical studies in the years to come.” He added “We have worked successfully in the past with the ICRF on our lead product Theragyn and we are very pleased to be working with them again on this new cancer product which we believe has substantial market potential. However, drug development is risky and there is no certainty that Therex will be successful.”

Dragon Pharmaceuticals of Top Quality

Cut Mix 150

Injectable Anabolic Steroid
Principal Component: Testosterone Propionate, Drostanolone Propionate, Trenbolone Acetate
Branded by: Dragon Pharma LLC
Unit: 1 X 10 ml (150 mg/ml)

Sustanon 350 - Cheap Price

Administration: Injection
Basic Constituent: Testosterone Blend
Produced by: Dragon Pharmaceutical
Amount: 20 x 10 mL vial (350 mg/mL)
Price: 20 x $40.00

Cypionat 250

Injectable Anabolic Steroid
Base Component: Testosterone Cypionate
Producer: Dragon Pharma LLC
Pack: 1 X 10 ml (250 mg/ml)

Cut Long 300

Injectable Anabolic Steroid
Active Constituent: Drostanolone Enanthate, Testosterone Enanthate, Trenbolone Enanthate
Branded by: Dragon Pharma Labs
Pack: 1 X 10 ml (300 mg/ml)

Propionat 100 - Bulk Price

Administration: Injection
Primary Component: Testosterone Propionate
Branded by: Dragon Pharmaceutical
Package: 10 x 10 mL vial (100 mg/mL)
Price: 10 x $30.00

Masteron 100 - Discount Price

Administration: Injection
Basal Chemical Name: Drostanolone Di-Propionate
Made by: Dragon Pharmaceutical
Package: 30 x 10 mL vial (100 mg/mL)
Price: 30 x $35.00

Oxymetholon - Discount Price

Administration: Oral
Basal Chemical Name: Oxymetholone
Producer: Dragon Pharma
Pack: 30 x 100 pastilles (50 mg/tab)
Price: 30 x $51.00

Dianabol

Natural Anabolic Steroidal Agent
Base Substance: Methandrostenolone
Branded by: Dragon Pharmaceuticals
Unit: 1 X 100 pastilles (20 mg/tablet)

Trenbolone 200 - Bulk Price

Administration: Injection
Active Component: Trenbolone Enanthate
Producer: Dragon Pharmaceutical
Amount: 10 x 10 mL vial (200 mg/mL)
Price: 10 x $77.00

Deca 300

Injectable Anabolic Steroid
Base Substance: Nandrolone Decanoate
Manufacturer: Dragon Pharmaceuticals
Unit: 1 X 10 ml (300 mg/ml)

Cut Mix 150 - Discount Price

Administration: Injection
Base Chemical Name: Testosterone Propionate, Drostanolone Propionate, Trenbolone Acetate
Branded by: Dragon Pharma Labs
Pack: 30 x 10 mL vial (150 mg/mL)
Price: 30 x $36.00

Primobolan 200

Injectable Steroid for Muscle Growth
Base Constituent: Methenolone Enanthate
Branded by: Dragon Pharma LLC
10 mL Sterile Multi-dose Vial (200 mg/mL)